NCT03300960 is a Phase 3 clinical trial of Provera 10 mg. in Infertility, sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA.

Who is sponsoring NCT03300960?

NCT03300960 is sponsored by Instituto Valenciano de Infertilidad, IVI VALENCIA.

What drugs are being tested in NCT03300960?

Interventions in NCT03300960: Provera 10 mg., Ganirelix (GnRH antagonist).

What condition does NCT03300960 study?

NCT03300960 studies Infertility.

Is NCT03300960 still recruiting?

NCT03300960 is currently completed. Last updated 25 August 2021.

Last reviewed 2021-08-25 · How we verify

NCT03300960

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation

Completed Phase 3 Last updated 25 August 2021

What this trial tests

Phase 3 trial testing Provera 10 mg. in Infertility in 318 participants. Completed in 25 June 2019.

Timeline

20 October 2017

Primary endpoint
25 June 2019

25 June 2019

Quick facts

Lead sponsor	Instituto Valenciano de Infertilidad, IVI VALENCIA
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	318
Start date	20 October 2017
Primary completion	25 June 2019
Estimated completion	25 June 2019
Sites	1 location across Spain

Drugs / interventions tested

Provera 10 mg. — full drug profile →
Ganirelix (GnRH antagonist) — full drug profile →

Conditions studied

Infertility — all drugs for Infertility →

Sponsor

Instituto Valenciano de Infertilidad, IVI VALENCIA — full company profile →

Who can join

Adults 18 to 35, female only, with Infertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether Medroxyprogesterone Acetate (MPA) administration in follicular phase prevents premature luteinization with equal efficiency as GnRH antagonists and otains similar clinical results in oocyte donation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.
Giles J, Alama P, Gamiz P, Vidal C, et al · · 2021 · cited 44× · PMID 33814126 · DOI 10.1016/j.fertnstert.2021.02.036
Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle.
Glujovsky D, Pesce R, Miguens M, Sueldo C, et al · · 2023 · cited 7× · PMID 38032057 · DOI 10.1002/14651858.cd013827.pub2

Verify or expand the search:

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Other Instituto Valenciano de Infertilidad, IVI VALENCIA trials

Trials by the same sponsor.

NCT06193135 — Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitar · NA · recruiting
NCT06384794 — Study of the ZyMōt Sperm Selection Method and Its Effect on Embryo Ploidy. · NA · recruiting
NCT06103383 — Second Phase of the Pilot Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women · NA · unknown
NCT05440019 — Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration · completed
NCT05161338 — Impact of Vaginal Microbiome on Vaginal Absorption of Exogenous Progesterone: a Pilot Study. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03300960 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Valenciano de Infertilidad, IVI VALENCIA
Last refreshed: 25 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03300960.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing